These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 35013803)

  • 1. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance Evaluation of Montelukast Pediatric Formulations: Part I-Age-Related In Vitro Conditions.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):26. PubMed ID: 35013835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):287. PubMed ID: 33063245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.
    Martir J; Flanagan T; Mann J; Fotaki N
    AAPS PharmSciTech; 2020 Oct; 21(7):282. PubMed ID: 33051713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation and In Vitro Evaluation of Montelukast Sodium-Loaded 3D Printed Orodispersible Films for the Treatment of Asthma.
    Özcan-Bülbül E; Kalender Y; Bal-Öztürk A; Üstündağ-Okur N
    AAPS PharmSciTech; 2024 Sep; 25(7):218. PubMed ID: 39289238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    J Pharm Sci; 2021 Dec; 110(12):3874-3888. PubMed ID: 34530004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration.
    O'Dwyer PJ; Box KJ; Dressman J; Griffin BT; Henze LJ; Litou C; Pentafragka C; Statelova M; Vertzoni M; Reppas C
    J Pharm Pharmacol; 2021 Mar; 73(4):437-446. PubMed ID: 33793836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.
    Arnold DH; Van Driest SL; Reiss TF; King JC; Akers WS
    J Clin Pharmacol; 2021 Mar; 61(3):360-367. PubMed ID: 32960980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast microsuspension with hypromellose for improved stability and oral absorption.
    Lee HR; Park HJ; Park JS; Park DW; Ho MJ; Kim DY; Lee HC; Kim EJ; Song WH; Park JS; Choi YS; Kang MJ
    Int J Biol Macromol; 2021 Jul; 183():1732-1742. PubMed ID: 34051251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation and evaluation of a montelukast sodium orally disintegrating tablet with a similar dissolution profile as the marketed product.
    Chen Y; Feng T; Li Y; Du B; Weng W
    Pharm Dev Technol; 2017 Mar; 22(2):168-172. PubMed ID: 26654222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension.
    Statelova M; Holm R; Fotaki N; Reppas C; Vertzoni M
    AAPS J; 2020 Nov; 22(6):146. PubMed ID: 33184711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions.
    Statelova M; Holm R; Fotaki N; Reppas C; Vertzoni M
    AAPS J; 2020 Sep; 22(6):126. PubMed ID: 33000297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Montelukast medicines of today and tomorrow: from molecular pharmaceutics to technological formulations.
    Barbosa JS; Almeida Paz FA; Braga SS
    Drug Deliv; 2016 Nov; 23(9):3257-3265. PubMed ID: 27011101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive tools and critical strategies for development of best fit PBPK model aiming better in vitro-in vivo correlation.
    Golhar A; Pillai M; Dhakne P; Rajput N; Jadav T; Sengupta P
    Int J Pharm; 2023 Aug; 643():123267. PubMed ID: 37488057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.